SCHEMBL2229247

SCHEMBL2229247

CNC(=O)c1ccc(Nc2nccc(-c3cn(C(C)C)c4cnccc34)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 11/20 0.58
EGFR P00533 3/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
KCNH2 Q12809 4/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
GSK3B P49841 2/20 0.45
NFATC1 O95644 1/20 0.45
DYRK1A Q13627 1/20 0.45
CCND1 P24385 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228832 0.92 CDK2 (0.48) CDK2EGFRKCNH2MKNK1MKNK2
SCHEMBL2227901 0.90 CDK2 (0.57) CDK2EGFRHDAC3HDAC4HDAC1
SCHEMBL2231144 0.89 STK17A (0.47) CDK2EGFRMKNK1MKNK2GSK3B
SCHEMBL2229939 0.89 MKNK1 (0.47) CDK2EGFRKCNH2MKNK1MKNK2
SCHEMBL2228830 0.88 EGFR (0.52) CDK2EGFRHDAC3HDAC4HDAC1
SCHEMBL2229891 0.88 CDK2 (0.58) CDK2EGFRHDAC3HDAC4HDAC1
SCHEMBL2227078 0.88 CDK2 (0.45) CDK2EGFRHDAC3HDAC4HDAC1
SCHEMBL2228876 0.88 CDK2 (0.45) CDK2KCNH2MKNK1MKNK2GSK3B
SCHEMBL2228372 0.86 GSK3B (0.50) CDK2EGFRMKNK1MKNK2GSK3B
SCHEMBL2228413 0.85 GSK3B (0.44) CDK2KCNH2MKNK1MKNK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
WO-2010042337-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY BRIX1, REL, CNKSR1 CDK2 381/4885EGFR 1962/4885HDAC3 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.